Seagen to Host Conference Call and Webcast Discussion on September 21, 2021 to Discuss TIVDAK™ (tisotumab vedotin-tftv) Approval

Seagen Inc. (Nasdaq: SGEN) will host a conference call and webcast on Tuesday, September 21, 2021 to discuss the U.S. Food and Drug Administration approval of TIVDAK (tisotumab vedotin-tftv).

Metadata
Provider: 
Business Wire, Inc.Business Wire, Inc.
Retrieved on: 
Monday, September 20, 2021
Information
Tags: 
Science, Biotechnology, Research, Pharmaceutical, Oncology, General Health, Health, Clinical Trials, Investor, Union, Food, Twitter, Webcast, European Union, Seagen, Inc., Regulation of food and dietary supplements by the U.S. Food and Drug Administration
Geotags: 
WASHINGTON, United States, SWITZERLAND, SEATTLE, CALIFORNIA, CANADA
⚠generated by AI ↴
Summary
Key Points: 
  • Seagen Inc. (Nasdaq: SGEN) will host a conference call and webcast on Tuesday, September 21, 2021 to discuss the U.S. Food and Drug Administration approval of TIVDAK (tisotumab vedotin-tftv).
  • Access to the event can be obtained as follows:
    6:00 a.m. Pacific Time / 9:00 a.m. Eastern Time
    Webcast with slides will be available at www.seagen.com in the Investors section .
  • Seagen is a global biotechnology company that discovers, develops and commercializes transformative cancer medicines to make a meaningful difference in peoples lives.
  • Seagen is headquartered in the Seattle, Washington area, and has locations in California, Canada, Switzerland and the European Union.


Seagen Inc. (Nasdaq: SGEN) will host a conference call and webcast on Tuesday, September 21, 2021 to discuss the U.S. Food and Drug Administration approval of TIVDAK™ (tisotumab vedotin-tftv). Access to the event can be obtained as follows:

September 21, 2021

6:00 a.m. Pacific Time / 9:00 a.m. Eastern Time

  • Telephone 844-763-8274 (U.S.) or +1 412-717-9224 (international); conference ID 10160278
  • Webcast with slides will be available at www.seagen.com in the Investors section. A webcast replay will be archived on the Company’s website.

About Seagen

Seagen is a global biotechnology company that discovers, develops and commercializes transformative cancer medicines to make a meaningful difference in people’s lives. Seagen is headquartered in the Seattle, Washington area, and has locations in California, Canada, Switzerland and the European Union. For more information on the company’s marketed products and robust pipeline, visit www.seagen.com and follow @SeagenGlobal on Twitter.

Copyright: 
Copyright Business Wire 2021